Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
105 hedge funds and large institutions have $585M invested in Marinus Pharmaceuticals, Inc in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 33 reducing their positions, and 19 closing their positions.
1,460% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $826K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more capital invested
Capital invested by funds: $411M → $585M (+$174M)
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
6% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 33
1% more funds holding
Funds holding: 104 → 105 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$5.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.68M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$4.14M |
| 4 |
Morgan Stanley
New York
|
+$4.02M |
| 5 |
BlackRock
New York
|
+$3.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.28M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.42M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$2.19M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.04M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.8M |
MRNS Hedge Fund Activity: Q4 2023 in Review
105 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2023, worth a combined $585M — up 42% from $411M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MRNS positions and 19 closed out — a net gain of 2 holders — while 35 added to existing stakes and 33 trimmed.
The largest buyer was Sofinnova Investments, adding an estimated $5.9M. The largest seller was Point72 Asset Management, cutting an estimated $4.28M.
- 105 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2023, up from 104 in Q3 2023.
- Funds reported $585M of Marinus Pharmaceuticals, Inc stock for Q4 2023, up 42% quarter-over-quarter.
- 21 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2023 and 19 closed out, a net change of +2 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q4 2023 was Sofinnova Investments, an estimated $5.9M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q4 2023 was Point72 Asset Management, an estimated $4.28M sold.
Based on aggregated 13F filings for Q4 2023.